According to CoinMeta, Rongchang Bio (09995. hk) announced that the company has signed a "License Agreement" with Yantai Rongchang Pharmaceutical, obtaining an exclusive global license for the pan-ras ( on ) small molecule inhibitor. The company will pay a upfront fee of 50 million yuan, with maximum milestone payments of 4.87 billion yuan, and will also pay royalties at a rate of 3%-7% of annual net sales. The introduction of this pan-ras ( on ) small molecule inhibitor project can complement the existing pipeline, broaden the company's oncology product portfolio, and create opportunities for future joint development with other assets within the company's pipeline.